The Covid-19 public health emergency is an unprecedented crisis that is radically changing our lives, putting us all to the test. We will only overcome it by acting together.
During a global emergency such as this, we must mobilize all available resources to overcome the challenges ahead. We are proud to contribute to finding solutions to this challenge facing humanity.
We are supporting everyone on the front line managing the Covid-19 public health emergency in Italy through a series of major initiatives using our wide-ranging experience gained from healthcare projects around the world.
We have acquired and imported, through a special airlift from China, electromedical equipment and personal protective equipment (PPE) for healthcare staff across Italy. Eni has sent huge quantities of critically needed surgical and advanced respirator masks to health facilities in Lombardy, Veneto, Emilia-Romagna, Le Marche, Basilicata, Puglia, Sicily and Sardinia. These supplies, which have been allocated on the basis of each facility’s needs, also include around 600 ventilators, portable oximeters, syringe pumps, patient monitors and intensive care beds.
Among many other commitments, which will total approximately €35 million, we are also the sole commercial partner in the creation of the Covid 2 Hospital in Rome.
We have made our HPC5 supercomputing infrastructure and molecular modelling skills freely available for coronavirus research, offering the highest quality tools and resources to the fight against this global emergency.
This collaboration is part of the European Exscalete4Cov initiative, which is bringing together leading institutions and research centres from Italy and across Europe to identify the safest and most promising drugs to tackle coronavirus. We are contributing to the project in partnership with Cineca, a non-profit research consortium that includes universities, national research centres and the Italian Ministry of Education, University and Research. Our joint team will carry out dynamic molecular simulations of viral proteins whose methods of infection are similar to Covid-19 to identify the most effective pharmaceutical compounds from a potential list of around 10,000. Following this, research will be carried out for new specific antiviral molecules through screening billions of molecular structures.
This website uses cookies to show you adverts and offer you services customised according to the preferences you have shown while browsing online. For further information please refer to our cookie policy.
Disclaimer
THIS WEBSITE (AND THE INFORMATION CONTAINED HEREIN) DOES NOT CONTAIN OR CONSTITUTE AN OFFER OF SECURITIES FOR SALE, OR SOLICITATION OF AN OFFER TO PURCHASE SECURITIES OR IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR FOR THE ACCOUNT OR BENEFIT OF ANY U.S. PERSON AS THAT TERM IS DEFINED IN THE SECURITIES ACT (A "U.S. PERSON"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH AN OFFER OR SOLICITATION WOULD REQUIRE THE APPROVAL OF LOCAL AUTHORITIES OR OTHERWISE BE UNLAWFUL (THE "OTHER COUNTRIES"). THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO THE CORRESPONDING REGULATIONS IN FORCE IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE “OTHER COUNTRIES” AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON UNLESS THE SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IS AVAILABLE. NO PUBLIC OFFERING OF SUCH SECURITIES IS INTENDED TO BE MADE IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN THE “OTHER COUNTRIES.”
In any Member State of the European Economic Area ("EEA"), the information contained in this website is only directed at and may only be communicated to persons who are "qualified investors" ("Qualified Investors") within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (the "Prospectus Regulation").
The information to which this website gives access is directed only at persons (i) who are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) who have professional experience in matters relating to investments falling within Article 19(5) of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates is only available to relevant persons and will be engaged in only with relevant persons, or in the EEA, with Qualified Investors. Any person who is not a relevant person, a Qualified Investor or otherwise permitted under applicable law or regulation to access the information, should not act or rely on the information contained herein.
Confirmation of Understanding and Acceptance of Disclaimer
These materials are for informational purposes only and are not directed to, nor are they intended for, access by persons located or resident in the United States, Australia, Canada, Japan or South Africa or any of the Other Countries. I certify that:
I am not resident of, or located in, the United States, Australia, Canada, Japan or South Africa or any of the Other Countries or I am not a U.S. Person; or
If I am a resident of, or located in, the EEA, I am a Qualified Investor within the meaning of Article 2(e) of the Prospectus Regulation; or
If I am a resident of, or located in, the United Kingdom, I am a Qualified Investor and a relevant person.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms and I am permitted under applicable law and regulations to proceed to the following parts of this website.
WARNING: the above certification constitutes a "self-certification" pursuant to Decree of the President of the Italian Republic No. 445 of 28 December 2000. False certifications are punishable by law.
